Keywords: Pan therapies, Market forecasts, Emerging agents, Johnson & Johnson, Tapentadol, Pfizer, Tanezumab, Takeda, Fulranumab, Decision Resources

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches

Article | 16 December 2012

The market for pain therapies will grow at an annual rate of 1.8% over the next 15 years, surpassing $49 billion in sales ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Pfizer

Johnson & Johnson

Takeda Pharmaceuticals

Go to company listing

Related Drugs

fulranumab

tanezumab

tapentadol

Go to drug listing